MX2009008822A - Metodo de tratamiento de canceres. - Google Patents

Metodo de tratamiento de canceres.

Info

Publication number
MX2009008822A
MX2009008822A MX2009008822A MX2009008822A MX2009008822A MX 2009008822 A MX2009008822 A MX 2009008822A MX 2009008822 A MX2009008822 A MX 2009008822A MX 2009008822 A MX2009008822 A MX 2009008822A MX 2009008822 A MX2009008822 A MX 2009008822A
Authority
MX
Mexico
Prior art keywords
treatment method
cancer treatment
mammal
invented
administration
Prior art date
Application number
MX2009008822A
Other languages
English (en)
Inventor
Connie Lynn Erickson-Miller
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690807&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009008822(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MX2009008822A publication Critical patent/MX2009008822A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se inventa un método para tratar cánceres y síndromes precancerosos en un mamífero, incluyendo un ser humano, que lo necesita, que comprende la administración de una cantidad terapéuticamente eficaz de un agonista no peptídico del receptor de TPO a dicho mamífero.
MX2009008822A 2007-02-16 2008-02-15 Metodo de tratamiento de canceres. MX2009008822A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US89023607P 2007-02-16 2007-02-16
US89255207P 2007-03-02 2007-03-02
US90820507P 2007-03-27 2007-03-27
US94934707P 2007-07-12 2007-07-12
US95228907P 2007-07-27 2007-07-27
US96919207P 2007-08-31 2007-08-31
US97721607P 2007-10-03 2007-10-03
PCT/US2008/054046 WO2008101141A2 (en) 2007-02-16 2008-02-15 Cancer treatment method

Publications (1)

Publication Number Publication Date
MX2009008822A true MX2009008822A (es) 2009-08-28

Family

ID=39690807

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008822A MX2009008822A (es) 2007-02-16 2008-02-15 Metodo de tratamiento de canceres.

Country Status (27)

Country Link
US (2) US20100075928A1 (es)
EP (1) EP2124547B1 (es)
JP (1) JP5511391B2 (es)
KR (1) KR101447763B1 (es)
CN (1) CN101662937B (es)
AR (1) AR065348A1 (es)
AU (1) AU2008216106B9 (es)
BR (1) BRPI0807940B8 (es)
CA (1) CA2678358C (es)
CR (1) CR10997A (es)
DK (1) DK2124547T3 (es)
EA (1) EA017715B1 (es)
ES (1) ES2675070T3 (es)
HU (1) HUE038563T2 (es)
IL (2) IL200319A (es)
MA (1) MA31202B1 (es)
MX (1) MX2009008822A (es)
NZ (1) NZ579068A (es)
PE (1) PE20081784A1 (es)
PL (1) PL2124547T3 (es)
PT (1) PT2124547T (es)
SI (1) SI2124547T1 (es)
TR (1) TR201809010T4 (es)
TW (1) TW200906393A (es)
UY (1) UY30915A1 (es)
WO (1) WO2008101141A2 (es)
ZA (1) ZA200905532B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
CN101888841B (zh) * 2007-10-09 2012-09-26 宾夕法尼亚大学理事会 血小板生成素受体激动剂(TpoRA)杀死急性人骨髓样白血病细胞
US8609693B2 (en) 2009-05-29 2013-12-17 Glaxosmithkline Llc Methods of administration of thrombopoietin agonist compounds
CN103079551A (zh) * 2010-09-01 2013-05-01 诺华有限公司 Hdac抑制剂与血小板减少症药物的组合
US9962370B2 (en) 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
PL3452053T3 (pl) * 2016-05-06 2023-05-08 Taris Biomedical Llc Sposób leczenia urotelialnego nowotworu złośliwego dolnych dróg
RU2675695C1 (ru) * 2018-03-06 2018-12-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ лечения рака предстательной железы высокого и очень высокого риска

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
CA2380206A1 (en) * 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Pharmaceutical compositions exhibiting thrombopoietin receptor agonism
ES2160560T1 (es) 1999-11-10 2001-11-16 Curacyte Ag Colorantes o,o'-dihidroxi-azoicos como constituyentes de medicamentos para el tratamiento de trombopenias.
AU783238B2 (en) * 1999-11-10 2005-10-06 Innatus Corporation Method and system to remove cytokine inhibitor in patients
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US6887890B2 (en) * 2000-05-30 2005-05-03 Chugai Seiyaku Kabushiki Kaisha Compounds exhibiting thrombopoietin-like activities
ATE292640T1 (de) * 2000-05-31 2005-04-15 Genzyme Corp Therapeutische verbindungen gegen eierstockkrebs
WO2002056912A2 (en) * 2001-01-16 2002-07-25 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
US7169931B2 (en) 2001-01-26 2007-01-30 Shionogi & Co., Ltd. Cyclic compounds exhibiting thrombopoietin receptor agonism
US20040063764A1 (en) 2001-01-26 2004-04-01 Hiroshi Takemoto Halogen compounds having thrombopoietin receptor agonism
EP1357116A4 (en) 2001-02-02 2005-06-01 Yamanouchi Pharma Co Ltd 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
JP2005510471A (ja) * 2001-09-24 2005-04-21 トスク インコーポレーティッド 減少した毒性のシスプラチン製剤及びそれを使用する方法
CA2472711C (en) 2002-01-18 2012-03-20 Yamanouchi Pharmaceutical Co., Ltd. 2-acylaminothiazole derivative or salt thereof
TWI280128B (en) 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
AU2003268687A1 (en) * 2002-09-30 2004-04-19 Yamanouchi Pharmaceutical Co., Ltd. Novel salt of 2-acylaminothiazole derivative
JP4895807B2 (ja) 2003-04-29 2012-03-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 変性疾患／損傷の治療方法
WO2005118551A2 (en) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
WO2006047344A1 (en) * 2004-10-25 2006-05-04 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
JP2009519352A (ja) 2005-11-23 2009-05-14 リガンド・ファーマシューティカルズ・インコーポレイテッド トロンボポエチン活性調節化合物および方法
MX2008011666A (es) 2006-03-15 2008-10-17 Ligand Pharm Inc Sintesis de compuestos que modulan la actividad de la trombopoyetina.

Also Published As

Publication number Publication date
PE20081784A1 (es) 2009-01-25
HUE038563T2 (hu) 2018-10-29
BRPI0807940A2 (pt) 2013-07-30
AR065348A1 (es) 2009-06-03
MA31202B1 (fr) 2010-02-01
US20100075928A1 (en) 2010-03-25
CA2678358C (en) 2015-12-08
UY30915A1 (es) 2008-09-02
CN101662937A (zh) 2010-03-03
KR101447763B1 (ko) 2014-10-07
KR20090113330A (ko) 2009-10-29
US20090022814A1 (en) 2009-01-22
ES2675070T3 (es) 2018-07-06
CN101662937B (zh) 2014-03-12
PT2124547T (pt) 2018-07-04
EA200970776A1 (ru) 2010-02-26
IL200319A0 (en) 2010-04-29
EP2124547A2 (en) 2009-12-02
EP2124547B1 (en) 2018-03-28
BRPI0807940B8 (pt) 2021-05-25
IL238394B (en) 2018-05-31
WO2008101141A3 (en) 2008-10-16
NZ579068A (en) 2012-05-25
EA017715B1 (ru) 2013-02-28
CR10997A (es) 2009-10-16
IL200319A (en) 2015-05-31
AU2008216106B2 (en) 2013-07-11
BRPI0807940B1 (pt) 2020-10-27
JP5511391B2 (ja) 2014-06-04
TR201809010T4 (tr) 2018-07-23
IL238394A0 (en) 2015-06-30
EP2124547A4 (en) 2010-05-05
CA2678358A1 (en) 2008-08-21
TW200906393A (en) 2009-02-16
PL2124547T3 (pl) 2018-08-31
ZA200905532B (en) 2010-04-28
WO2008101141A2 (en) 2008-08-21
DK2124547T3 (en) 2018-07-16
SI2124547T1 (en) 2018-08-31
AU2008216106B9 (en) 2013-09-05
AU2008216106A1 (en) 2008-08-21
JP2010519221A (ja) 2010-06-03

Similar Documents

Publication Publication Date Title
MX2009008822A (es) Metodo de tratamiento de canceres.
MX2013012253A (es) Conjugados novedosos de aglutinante-farmaco (adc) y su uso.
IL200193A0 (en) Combination of lbh589 with other therapeutic agents for treating cancer
PL2601962T3 (pl) Schemat dawkowania LAG-3 do stosowania w leczeniu raka
HK1139930A1 (en) Cyclopamine lactam analogs and methods of use thereof
ZA201004403B (en) Therapeutic cancer treatments
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
IL207532A0 (en) Glp-1 receptor agonists and related phamaceutical ingredients for the treatment of cancer
HK1163119A1 (en) Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4
HK1170505A1 (en) Methods of treating notch1-antagonist-resistant cancer(s) using notch3 antagonists 3 1
EP2173740A4 (en) INHIBITORS OF HEMOXYGENASE AND THEIR USE IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM
IL210810B (en) Peptides to treat pain and/or inflammation
EP2165715A4 (en) THERAPEUTIC AGENT FOR CANCER AND METHOD FOR TREATING CANCER
IL201422A0 (en) Therapeutic agents useful for treating pain
MY176031A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
IL201460A0 (en) Phthalazinone derivatives and their use as medicament to treat cancer
EP2359781A4 (en) DEVICE FOR IMPLEMENTING BEAUTY, PHYSIOTHERAPY AND HYDROTHERAPY TREATMENTS
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
HK1209053A1 (zh) 地來西坦在慢性疼痛的治療中的用途
IL201635A0 (en) Medicaments and methods to treat autoimmune disease and cancer
EP2144887A4 (en) PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
TN2009000490A1 (en) Cancer treatment combination therapy comprising vinflunine and trastuzumab
PT2320900T (pt) Utilização de opioides ou miméticos de opioides para o tratamento de pacientes com cancros resistentes
ZA200904478B (en) Novel therapeutic use for treating leukaemia
EP2124950A4 (en) PAIN TREATMENT WITH NALOXONE

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status